Antiviral therapy

Although direct-acting antiviral ( DAA ) therapies for chronic hepatitis C virus ( HCV ) infection have demonstrated high rates...


Revolade ( Eltrombopag ) is used in adults for the treatment of: • long-term immune thrombocytopenic purpura ( ITP ), a...


A study has evaluated the clinical outcomes of Telaprevir- or Simeprevir-based triple therapy for recurrent hepatitis C after living donor...


Favourable efficacy and safety profiles for Simeprevir ( Olysio ) in combination with Pegylated interferon alpha ( PEG-IFN alpha )...


Herpes zoster is common and vaccine preventable. Stroke risk may be increased following zoster, but evidence is sparse and could...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in...


Results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 ( HIV-1 ) co-infection ( TURQUOISE-I...


Hepatitis C virus ( HCV ) infects more than 185 million individuals worldwide. Twenty percent of patients chronically infected with...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in...


In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor Sofosbuvir ( Sovaldi ) and the antiviral drug...


Eltrombopag ( United States: Promacta; Europe: Revolade ), in addition to the approval for severe aplastic anemia in the U.S.,...


An Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ), the nonnucleoside polymerase inhibitor ABT-333, and Ribavirin...


Idenix Pharmaceuticals has announced interim data from the ongoing phase II 12-week HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral...


Maraviroc ( Celsentri, Selzentry ), a chemokine co-receptor type 5 ( CCR5 ) antagonist, has demonstrated comparable efficacy and safety...


ZMapp is an experimental treatment, developed by Mapp Biopharmaceutical, for use with individuals infected with Ebola virus. It has not...


Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented at the International Liver Congress 2014 showed that...


The FDA ( Food and Drug Administration ) has approved Olysio ( Simeprevir ), an NS3/4A protease inhibitor, for the...


The approval of two hepatitis C virus ( HCV ) protease inhibitors by the FDA ( Food and Drug Administration...


Improved understanding of HCV replication has allowed for the development of new therapeutic agents that target enzymes directly. HCV is...


The challenge of new therapeutic agents and combinations is to improve virological response, shorten the length of therapy and offer...